Asher Mullard
#87,959
Most Influential Person Now
Asher Mullard's AcademicInfluence.com Rankings
Asher Mullardbiology Degrees
Biology
#3886
World Rank
#5884
Historical Rank
Neuroscience
#385
World Rank
#403
Historical Rank
Biochemistry
#384
World Rank
#457
Historical Rank

Download Badge
Biology
Asher Mullard's Degrees
- PhD Biochemistry University of California, San Francisco
- Bachelors Biology Stanford University
Similar Degrees You Can Earn
Why Is Asher Mullard Influential?
(Suggest an Edit or Addition)Asher Mullard's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Palmitoylation of huntingtin by HIP14is essential for its trafficking and function (2006) (323)
- Huntingtin-Interacting Protein HIP14 Is a Palmitoyl Transferase Involved in Palmitoylation and Trafficking of Multiple Neuronal Proteins (2004) (322)
- Protein–protein interaction inhibitors get into the groove (2012) (240)
- COVID-19 vaccine development pipeline gears up (2020) (190)
- FDA approves 100th monoclonal antibody product (2021) (176)
- Maturing antibody–drug conjugate pipeline hits 30 (2013) (164)
- Deuterated drugs draw heavier backing (2016) (153)
- Targeted protein degraders crowd into the clinic (2021) (152)
- New drugs cost US$2.6 billion to develop (2014) (147)
- 2011 FDA drug approvals (2012) (144)
- 2018 FDA drug approvals (2019) (139)
- 2012 FDA drug approvals (2013) (133)
- How COVID vaccines are being divvied up around the world. (2020) (112)
- Merck &Co. drops osteoporosis drug odanacatib (2016) (111)
- 2010 FDA drug approvals (2011) (107)
- FDA approves first CAR T therapy (2017) (106)
- 2014 FDA drug approvals (2015) (101)
- Maturing antibody–drug conjugate pipeline hits 30 (2013) (100)
- Reliability of 'new drug target' claims called into question (2011) (100)
- 2019 FDA drug approvals (2020) (99)
- 2013 FDA drug approvals (2014) (97)
- Sting of Alzheimer's failures offset by upcoming prevention trials (2012) (97)
- First targeted protein degrader hits the clinic (2019) (96)
- 2016 FDA drug approvals (2017) (91)
- Drug repurposing programmes get lift off (2012) (85)
- Presynaptic Trafficking of Synaptotagmin I Is Regulated by Protein Palmitoylation* (2004) (83)
- Parsing clinical success rates (2016) (80)
- 2015 FDA drug approvals (2016) (76)
- Mediator scandal rocks French medical community (2011) (75)
- Landmark Alzheimer’s drug approval confounds research community (2021) (75)
- 2010 FDA drug approvals (2011) (73)
- Microbiology: The inside story (2008) (71)
- 2017 FDA drug approvals (2018) (71)
- NCI-MATCH trial pushes cancer umbrella trial paradigm (2015) (70)
- From the editors (2007) (65)
- BACE inhibitor bust in Alzheimer trial (2017) (64)
- FDA approves fourth CAR-T cell therapy (2021) (63)
- The drug-maker's guide to the galaxy (2017) (62)
- Cracking KRAS (2019) (61)
- New checkpoint inhibitors ride the immunotherapy tsunami (2013) (58)
- New vaccine coalition targets epidemics (2016) (57)
- European Lead Factory opens for business (2013) (57)
- Alzheimer amyloid hypothesis lives on (2016) (57)
- Flooded by the torrent: the COVID-19 drug pipeline (2020) (54)
- FDA approves landmark RNAi drug (2018) (49)
- Phosphatases start shedding their stigma of undruggability (2018) (47)
- DNA tags help the hunt for drugs (2016) (46)
- NLRP3 inhibitors stoke anti-inflammatory ambitions (2019) (44)
- The cancer vaccine resurgence (2016) (43)
- FDA approves first BCMA-targeted CAR-T cell therapy (2021) (39)
- Fragile X disappointments upset autism ambitions (2015) (38)
- Drug developers reboot anti-NGF pain programmes (2015) (37)
- What does AlphaFold mean for drug discovery? (2021) (36)
- Pioneering apoptosis-targeted cancer drug poised for FDA approval (2016) (36)
- 2017 FDA drug approvals (2015) (35)
- The phenotypic screening pendulum swings (2015) (35)
- Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating (2020) (35)
- Can innate immune system targets turn up the heat on 'cold' tumours? (2017) (35)
- Cancer metabolism pipeline breaks new ground (2016) (35)
- Stem-cell discovery platforms yield first clinical candidates (2015) (34)
- Biotech R&D spend jumps by more than 15% (2016) (34)
- Restoring IL-2 to its cancer immunotherapy glory (2021) (33)
- FDA approves dupilumab for severe eczema (2017) (32)
- Could pharma open its drug freezers? (2011) (32)
- Can next-generation antibodies offset biosimilar competition? (2012) (31)
- FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm (2021) (31)
- IDO takes a blow (2018) (31)
- Gene therapy community grapples with toxicity issues, as pipeline matures (2021) (30)
- Nine paths to PCSK9 inhibition (2017) (29)
- The anticounterfeiter's technological tool kit (2010) (28)
- Experimental Ebola drugs enter the limelight (2014) (28)
- FDA rejects NASH drug (2020) (27)
- Arvinas’s PROTACs pass first safety and PK analysis (2019) (27)
- Anti-amyloid failures stack up as Alzheimer antibody flops (2019) (26)
- FDA approves first deuterated drug (2017) (26)
- Gene-editing pipeline takes off (2020) (25)
- BACE failures lower AD expectations, again (2018) (25)
- Controversial Alzheimer’s drug approval could affect other diseases (2021) (25)
- Pioneering apoptosis-targeted cancer drug poised for FDA approval (2016) (24)
- Learning from exceptional drug responders (2014) (24)
- Cholesterol-lowering blockbuster candidates speed into Phase III trials (2012) (23)
- Biomolecular condensates pique drug discovery curiosity (2019) (23)
- 2021 FDA approvals (2022) (23)
- Microglia-targeted candidates push the Alzheimer drug envelope (2018) (23)
- Re-assessing the rule of 5, two decades on (2018) (22)
- Drug withdrawal sends critical care specialists back to basics (2011) (22)
- Addressing cancer’s grand challenges (2020) (22)
- Jim O'Neill (2016) (22)
- EMA reconsiders 'read-through' drug against Duchenne muscular dystrophy following appeal (2014) (21)
- FDA approves Eli Lilly's baricitinib (2018) (21)
- BTK inhibitors get a boost (2017) (21)
- FDA approves second BCMA-targeted CAR-T cell therapy (2022) (20)
- Bispecific antibody pipeline moves beyond oncology (2017) (20)
- GSK's darapladib failures dim hopes for anti-inflammatory heart drugs (2014) (20)
- Second anticancer CAR T therapy receives FDA approval (2017) (20)
- Small molecules against RNA targets attract big backers (2017) (19)
- FDA approves first immunotherapy combo (2015) (18)
- A probe for every protein (2019) (17)
- FDA approves first bispecific (2014) (17)
- Anti-ageing pipeline starts to mature (2018) (17)
- Oncologists tap the microbiome in bid to improve immunotherapy outcomes (2018) (17)
- Microbiology: Tinker, bacteria, eukaryote, spy (2009) (17)
- Patient-focused drug development programme takes first steps (2013) (17)
- Antibody–oligonucleotide conjugates enter the clinic (2021) (16)
- Machine learning brings cell imaging promises into focus (2019) (16)
- Chinese biopharma starts feeding the global pipeline (2017) (15)
- p53 programmes plough on (2020) (15)
- Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure (2016) (15)
- Partnering between pharma peers on the rise (2011) (14)
- Gene therapies advance towards finish line (2011) (14)
- Targeted degraders clear first safety hurdles (2020) (14)
- Pioneering antisense drug heads into pivotal trials for Huntington disease (2019) (14)
- Bispecific antibody pipeline moves beyond oncology (2017) (14)
- On the origin of transformative drugs (2018) (14)
- The Roadmap Epigenomics Project opens new drug development avenues (2015) (14)
- FDA approves landmark tissue-agnostic cancer drug (2018) (14)
- FDA approves first-in-class cancer metabolism drug (2017) (14)
- First approval of a complement C3 inhibitor opens up autoimmune and inflammatory opportunities (2021) (13)
- Hearing shines spotlight on biosimilar controversies (2010) (13)
- Top product sales forecasts for 2018 (2018) (13)
- mRNA vaccines get another booster (2018) (13)
- EMA greenlights second gene therapy (2016) (13)
- FDA approves antitoxin antibody (2016) (13)
- How much do phase III trials cost? (2018) (13)
- Stemming the tide of drug resistance in cancer (2020) (13)
- Synthetic lethality screens point the way to new cancer drug targets (2017) (13)
- Synthetic lethality screens point the way to new cancer drug targets (2017) (13)
- Momentum builds around new antibiotic business models (2014) (12)
- RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape (2021) (12)
- FDA approves ADC Therapeutics’ loncastuximab tesirine, ushering in a new cytotoxic payload (2021) (12)
- FDA approves first-in-class SYK inhibitor (2018) (12)
- 2011 in reflection (2012) (12)
- Long COVID’s long R&D agenda (2021) (12)
- Next-generation proteasome blockers promise safer cancer therapy (2012) (12)
- FDA approves second GPCR-targeted antibody (2018) (11)
- Achaogen bankruptcy highlights antibacterial development woes (2019) (11)
- Cancer market hits $100 billion (2015) (11)
- Cancer reproducibility project yields first results (2017) (11)
- FDA approves AstraZeneca’s anifrolumab for lupus (2021) (11)
- Gene silencing: Shhh! RNAi-dependent and -independent pathways at work (2007) (11)
- FDA approves first-in-class osteoporosis drug (2019) (11)
- FDA approves first new flu drug in 20 years (2018) (11)
- PRIME time at the EMA (2017) (11)
- FDA approves Novartis's CDK4/6 inhibitor (2017) (11)
- Alnylam dealt blow (2009) (10)
- Microfluidics platform lowers barrier to drug combination screening (2018) (10)
- Pfizer exits neuroscience (2018) (10)
- Alzheimer prevention failure rattles field, anew (2019) (10)
- Multicompany trials adapt to disciplines beyond cancer (2014) (10)
- COVID-19 vaccines buoy hope (2020) (10)
- Anti-IL-6Rs falter in COVID-19 (2020) (10)
- Malaria medicine box expands (2018) (10)
- DNA-encoded drug libraries come of age (2016) (10)
- Oral GLP1 analogue rounds Phase II corner (2015) (10)
- Alzheimer prevention hopes continue to dim (2020) (10)
- Novartis secures first CRISPR pharma collaborations (2015) (10)
- Unleashing the Mini-Sentinel (2012) (10)
- FDA approves splice-modulating drug (2017) (10)
- Use of personalized cancer drugs runs ahead of the science (2015) (9)
- FDA rejects first cognitive claim for antidepressant (2016) (9)
- RNAi hits another rut (2016) (9)
- 23andMe sets sights on UK/Canada, signs up Genentech (2015) (9)
- Bracing for the biosimilar wave (2017) (9)
- ALS antisense drug falters in phase III (2021) (9)
- IRAK4 degrader to take on innate immunity (2020) (9)
- EU implicated in controversial counterfeiting bill (2010) (9)
- More Alzheimer’s drugs head for FDA review: what scientists are watching (2021) (9)
- Painkilling anti-NGF antibodies stage phase III comeback (2018) (9)
- FDA approves first anti-ANGPTL3 antibody, for rare cardiovascular indication (2021) (9)
- Symptomatic AD treatment fails in first phase III (2016) (9)
- Immunotherapy interest drives IDO deals (2015) (9)
- FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on (2018) (9)
- Calls grow to tap the gold mine of human genetic knockouts (2017) (9)
- PCSK9 inhibitors are go (2015) (9)
- First antibody against COVID-19 spike protein enters phase I (2020) (9)
- Cancer stem cell candidate Rova-T discontinued (2019) (9)
- Success of immunomodulators in MS shifts discovery focus to neuroprotection (2011) (9)
- Gene therapy boom continues (2019) (8)
- EMA greenlights Novartis' first-in-class IL-17 inhibitor (2014) (8)
- FDA approves first all-oral sleeping sickness drug (2021) (8)
- EMA opens its data vaults (2016) (8)
- Amgen overcomes historically undruggable target, with FDA nod for first KRAS inhibitor (2021) (8)
- Coordinating the COVID-19 pipeline (2020) (8)
- FDA approves antibody cocktail for Ebola virus (2020) (8)
- Accelerated approval dust begins to settle (2011) (8)
- DNA repair: Making the cut (2006) (8)
- PARP inhibitor pick-me-up (2019) (8)
- FDA approvals for the first 6 months of 2016 (2016) (7)
- European regulators approve first PARP inhibitor (2014) (7)
- New plaque psoriasis approval carries suicide warning (2017) (7)
- Phase III setback for lead angiopoietin inhibitor (2014) (7)
- New cancer vaccines show clinical promise (2017) (7)
- Molecular imaging as a de-risking tool: coming into focus? (2013) (7)
- US drug spending hits $425 billion (2016) (7)
- FDA approves an inhibitor of a novel ‘epigenetic writer’ (2020) (7)
- FDA approves first peanut allergy drug (2020) (7)
- PARP inhibitors plough on (2017) (7)
- Anti-tau antibody failures stack up (2021) (7)
- Reining in the supersized Phase I cancer trial (2016) (7)
- Ebola outbreak prompts experimental drug rollout (2018) (7)
- $215 million precision-medicine initiative takes shape (2015) (7)
- 2013 in reflection (2013) (7)
- Tackling antimicrobial drug resistance (2016) (7)
- Crowdfunding clinical trials (2015) (7)
- Trispecific antibodies take to the clinic (2020) (7)
- Parkinson disease repurposing promise (2017) (7)
- EMA rewrites Phase I guidelines in aftermath of FAAH tragedy (2016) (7)
- Industry R&D returns slip (2015) (6)
- Industry advances landmark CRISPR candidate into the clinic (2018) (6)
- The art of losing (2015) (6)
- N-of-1 drugs push biopharma frontiers (2020) (6)
- Merck readies oral, macrocyclic PCSK9 inhibitor for phase II test (2021) (6)
- R&D returns continue to fall (2016) (6)
- Off-label targeted cancer drugs fail in first randomized trial (2015) (6)
- Finding fault with Bial's fatal FAAH inhibitor (2017) (6)
- Pfizer expands hunt for immuno-oncology biomarkers (2016) (6)
- Can you trust your cancer cell lines? (2018) (6)
- Once-yearly device takes on daily and weekly diabetes drugs (2014) (6)
- First in vivo gene-editing drugs enter the clinic (2017) (6)
- FDA approves first digital pill (2017) (6)
- FDA rejects first DARPin (2020) (6)
- FDA approves two IBS drugs (2015) (6)
- Immune evasion: Overcoming defensins (2008) (6)
- Drug makers and NIH team up to find and validate targets (2014) (6)
- First in vivo CRISPR candidate enters the clinic (2019) (6)
- FDA approves first marijuana-derived product (2018) (6)
- Fragment-based screening sees the light (2020) (6)
- Hints of hope with remdesivir (2020) (6)
- Synthetic lethality screens point the way to new cancer drug targets (2017) (6)
- PCSK9-lowering RNAi contender clears first phase III trial (2019) (6)
- FDA approves first new ALS drug in over 20 years (2017) (5)
- FDA approves ultra-orphan drug on a 4-patient trial (2015) (5)
- CETP set-back, again (2015) (5)
- Priority review voucher pitfalls (2015) (5)
- 2016 EMA drug approval recommendations (2017) (5)
- LAG3 pushes immuno-oncology’s leading edge (2022) (5)
- FDA approves first EGFR exon 20 targeted kinase inhibitor (2021) (5)
- New hope for anti-obesity drugs (2021) (5)
- FDA approves anticoagulant antidote (2015) (5)
- A snapshot of lead-generation strategies (2018) (5)
- FDA approves first BCMA-targeted therapeutic (2020) (5)
- Green light for Janssen's IL-6 blocker (2014) (5)
- Roche’s anti-TIGIT drug suffers a phase III cancer setback (2022) (5)
- Fragile X drug development flounders (2016) (5)
- Preclinical antibiotic pipeline gets a pick-me-up (2017) (5)
- Do you want chips with that? (2015) (5)
- Straight talk with...Phil Willis (2011) (5)
- FDA approves first drug for primary progressive multiple sclerosis (2017) (5)
- Pfizer’s COVID-19 vaccine secures first full FDA approval (2021) (5)
- Remyelination researchers regroup after proof-of-concept setback in multiple sclerosis (2016) (5)
- Making way for maternal immunization (2015) (5)
- FDA approves first GPCR biased agonist (2020) (5)
- Finding the way with LIPID MAPS (2008) (5)
- COVID-19 platform trial delivers (2020) (5)
- EMA recommended 35 new drugs in 2017 (2018) (5)
- Oncology trials gear up for high-throughput sequencing (2012) (5)
- FDA notches up third tissue-agnostic cancer approval (2019) (5)
- What’s next for the synthetic lethality drug discovery engine? (2022) (4)
- Regulators approve the first cancer-killing virus (2015) (4)
- Affordable HIV and sickle cell disease gene therapies (2019) (4)
- FDA approves RNA-targeting small molecule (2020) (4)
- BACE race gains steam (2016) (4)
- COVID-19 vaccines start moving into advanced trials (2020) (4)
- COVID-19 brings drug development to a halt (2020) (4)
- Cancer charity sees success re-prioritizing industry's shelved compounds (2014) (4)
- FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform (2022) (4)
- FDA approvals for the first 6 months of 2015 (2015) (4)
- FDA approves first PSMA-targeted radiopharmaceutical (2022) (4)
- First de novo deuterated drug poised for approval (2022) (4)
- Pharmaceutical firms commit US$1 billion to antibiotic development (2020) (4)
- Single-cell profiling sheds new light (2011) (4)
- Reining in the supersized Phase I cancer trial (2016) (4)
- Daphne Koller (2019) (4)
- mRNA-based drug approaches Phase I milestone (2016) (4)
- Climbing cancer’s MYC mountain (2022) (4)
- Robust biotech sector increases R&D spend (2015) (4)
- Sanofi's dengue vaccine rounds final corner (2014) (4)
- HOTAIR rises: new role for non-coding RNAs (2007) (4)
- Dual fronts poised to transform melanoma therapy (2011) (4)
- Second chance for dronedarone after recent setback? (2012) (4)
- Amylyx’s ALS therapy secures FDA approval, as regulatory flexibility trumps underwhelming data (2022) (4)
- Regulators and industry tackle dose-finding issues (2015) (4)
- CETP inhibitors stumble on (2017) (4)
- Underground drug networks in the early days of AIDS (2014) (4)
- BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval (2022) (4)
- FDA approves decades-old maribavir for CMV infection (2021) (4)
- FDA approves fifth RNAi drug — Alnylam’s next-gen hATTR treatment (2022) (4)
- The long Avandia endgame (2011) (4)
- Sarepta’s DMD gene therapy falls flat (2021) (4)
- Cancer drug developers counteract kinase gatekeeper mutations (2015) (4)
- Economists propose a US$30 billion boost to biomedical R&D (2012) (4)
- Sepsis researchers set sights on immunotherapeutic strategies (2018) (4)
- FDA approves first drug for Parkinson disease psychosis (2016) (4)
- COVID-19 vaccine guidelines (2020) (4)
- COVID umbrella trials multiply (2020) (4)
- Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics (2022) (4)
- FDA authorizes first single-shot COVID-19 vaccine (2021) (4)
- Cardiovascular pipeline decline quantified (2016) (3)
- FDA approves first-in-class TSLP-targeted antibody for severe asthma (2022) (3)
- FDA approves first-in-class KRAS inhibitor. (2021) (3)
- Immuno-oncology target TIGIT attracts a new contender (2021) (3)
- The quest to prevent MS — and understand other post-viral diseases (2022) (3)
- Learning from the 2012–2013 class of breakthrough therapies (2013) (3)
- 2022 FDA approvals (2023) (3)
- Diabetes drug shows promise in Parkinson disease (2017) (3)
- WHO heads back to the drug development drawing board (2010) (3)
- Mechanisms of disease: Inhibiting γ-secretase activity (2007) (3)
- Outcome results renew debate about diabetes drug development. (2013) (3)
- Do you want chips with that? (2015) (3)
- Low-cost non-profit drug repurposing (2018) (3)
- FDA rejects first-in-class osteoporosis drug (2017) (3)
- 2011 in reflection (2012) (3)
- Boehringer Ingelheim experiments with open-access chemical probes (2017) (3)
- KRAS’s undruggability cracks? (2019) (3)
- Bank tests drug development waters (2014) (3)
- Paring down the placebo response (2016) (3)
- Cell signalling: Asymmetry in action (2006) (3)
- Faecal matter transplants boost immuno-oncology efficacy (2021) (3)
- Fitness partners beat the heat (2007) (3)
- RNAi agents score an approval and drive an acquisition (2019) (3)
- Bacteria could help control dengue fever (2009) (3)
- Tezepelumab prepares to enter the asthma antibody fray (2021) (3)
- Supersized virtual screening offers potent leads (2019) (3)
- Built-to-buy start-ups begin to bloom (2014) (3)
- Leading microbiome-based therapeutic falters in Phase II trial (2016) (3)
- $1.3 billion per drug? (2020) (3)
- The FDA approves a first farnesyltransferase inhibitor (2020) (3)
- Pharmaceutical market growth set to slow? (2019) (2)
- Access to medicines report cards (2016) (2)
- COVID-19 vaccine success enables a bolder vision for mRNA cancer vaccines, says BioNTech CEO (2021) (2)
- COVID antibody drugs have saved lives — so why aren’t they more popular? (2022) (2)
- UK to train 2,000 new PhDs (2008) (2)
- Anti-inflammatory cardiovascular therapies take another hit (2018) (2)
- WHO report on drug development marred by big pharma leak (2010) (2)
- FDA approvals for the first 6 months of 2017 (2017) (2)
- Epigenomic colon cancer kit (2009) (2)
- Amarin agreement opens off-label promotion door (2016) (2)
- European regulators launch 'breakthrough' equivalent programme (2016) (2)
- Smallest biopharma firms are pushing more of the pipeline (2019) (2)
- REVAMPing antibiotic incentives (2018) (2)
- DNA damage response drugs for cancer yield continued synthetic lethality learnings (2022) (2)
- FDA approves female sexual dysfunction drug (2015) (2)
- Moncef Slaoui (2015) (2)
- Proliferation without differentiation (2008) (2)
- The BCMA bonanza (2019) (2)
- Post-translational modification: Picking apart polyubiquitin chains (2008) (2)
- Blood–brain barrier-traversing biologic secures regulatory approval, in Japan (2021) (2)
- NIAID amps up vaccine adjuvant work (2014) (2)
- Second CTLA4-targeted checkpoint inhibitor secures FDA approval (2022) (2)
- EMA recommended approval for 40 new drugs in 2014 (2015) (2)
- Biotech gender gap (2017) (2)
- Genetic biomarker trumps tissue type in landmark oncology approval (2017) (2)
- UK outlines its antibiotic pull incentive plan (2020) (2)
- Two competing RSV vaccines round final phase III corner (2022) (2)
- Failure of Seres’s phase II ulcerative colitis programme renews microbiome concerns (2021) (2)
- Biogen Idec enters hemophilia B market (2014) (2)
- Make or break for first splice-modulating agents (2013) (2)
- First-in-class tissue factor-targeted antibody–drug conjugate secures FDA approval (2021) (2)
- An audience with Jay Bradner (2017) (2)
- FDA approves first targeted drug for acute myelogenous leukaemia (2017) (2)
- FDA approves first haemophilia B gene therapy (2022) (2)
- EMA recommended 39 new drug approvals last year (2016) (2)
- The deadly burden of drug-resistant bacteria (2022) (2)
- Cancer drug approvals and setbacks in 2021 (2021) (2)
- EMA approves first ever malaria vaccine (2015) (2)
- NIH tackles clinical trial shortcomings (2016) (2)
- Novartis’s canakinumab stumbles in cancer, again (2021) (2)
- Accelerated approvals under the microscope (2021) (2)
- Straight talk with...Aline Plançon (2010) (2)
- Mediator scandal engulfs French compensation body (2013) (2)
- PDUFA V goes back to basics (2012) (2)
- FDA unveils searchable adverse events system (2017) (2)
- Vaccine failure explained (2008) (2)
- FDA outlines steps for individualized drug development (2021) (2)
- Tatsuya Kondo (2014) (1)
- Parkinson pipeline pare back (2021) (1)
- FDA approves oral version of diabetes biologic (2019) (1)
- Innovative antidepressants arrive (2019) (1)
- Should the FDA disclose complete response letters? (2015) (1)
- FDA plans Office of Drug Evaluation Science (2019) (1)
- Flagella and cilia come of age: Cilia and flagella formation and function (2010) (1)
- Development: Notch mediates the sprouting of tip cells (2007) (1)
- Ebola vaccine success (2017) (1)
- MDMA scores PTSD success in a landmark phase III trial (2021) (1)
- Cancer mouse models carry genomic inconsistencies (2017) (1)
- New naming scheme for antibodies drops the -mab stem (2022) (1)
- Development: Notch mediates the sprouting of tip cells (2007) (1)
- Therapeutic developments: Masters of medicine (2017) (1)
- Monoclonal antibodies show promise in phase I malaria trial (2021) (1)
- CRISPR technologies are going to need a bigger toolbox (2021) (1)
- $215 million cancer immunotherapy biomarker consortium debuts (2017) (1)
- Induced protein proximity drug discovery, from 30,000 feet (2022) (1)
- FDA advisory committee votes for approval of first microbiome-based drug, despite data problems (2022) (1)
- Pull incentives for antibiotics get push from the UK (2022) (1)
- Neglected disease R&D funding hits new high (2019) (1)
- Anti-CD3 antibody charts out a type 1 diabetes comeback (2019) (1)
- Nigel Blackburn (2017) (1)
- Panel meeting prompts excitement for antiobesity drug (2012) (1)
- Menelas Pangalos (2013) (1)
- What does Pfizer's merger mean for drug development? (2016) (1)
- FDA approves anti-CD3 antibody to delay type 1 diabetes onset (2022) (1)
- FDA approves first cardiac myosin inhibitor (2022) (1)
- Bracing for the biosimilar wave (2017) (1)
- Breakthrough programme turns two (2014) (1)
- FDA approves first-in-class HIV capsid inhibitor (2023) (1)
- Charting the decline of US biomedical research funding (2015) (1)
- Infectious Disease: Finding the keys to the placental barrier (2008) (1)
- Straight talk with...Ellen 't Hoen (2010) (1)
- NCI starts 'exceptional responder' hunt (2014) (1)
- Priority review vouchers miss the policy mark (2020) (1)
- FDA approves SMA gene therapy (2019) (1)
- Ebola vaccine yields first hopes of clinical efficacy (2015) (1)
- FDA approves first drug under new antibacterial and antifungal drug programme (2018) (1)
- CAR–T cell companies cash in (2015) (1)
- UK DNA database needs overhaul (2008) (1)
- From the editors (2007) (1)
- Hal Barron (2019) (1)
- Molecular motors: Power in numbers (2008) (1)
- Clinuvel's tanning agent nears approval for porphyria (2015) (1)
- Lipids: Orientating with PtdIns(3,4,5)P3 (2008) (1)
- Reflections on 10 years of the FDA’s breakthrough therapy designation (2022) (1)
- HIV vaccine suffers setback (2020) (1)
- Microscopy: Eukaryotic cell, now showing in 3D (2007) (1)
- Husseini Manji (2015) (1)
- Industry head-to-head trials favour sponsor (2015) (1)
- Understanding how microbiome bugs metabolize drugs (2019) (1)
- Biogen files ALS drug for FDA review, putting neuroscience-accelerated approvals back in the hot seat (2022) (1)
- Cancer model consortium debuts (2016) (1)
- Pliant’s integrin inhibitor boosted by phase II IPF data (2022) (1)
- Novartis' lung cancer ALK inhibitor approved (2014) (1)
- Cures Act shakes up the FDA and NIH (2016) (1)
- First biosimilar antibody nears US approval (2016) (1)
- John P. A. Ioannidis (2014) (1)
- Skin cancer on the rise (2009) (1)
- Malaria: Sticking around (2007) (1)
- Mechanisms of disease: Kinases out of control — brake line cut! (2007) (1)
- Cheating bacteria could treat infections (2009) (1)
- Steve Blank (2014) (1)
- Silent mutations turn up the volume (2007) (1)
- Large pharmas set up screening library data-sharing experiment (2019) (1)
- Roche snaps up another NLRP3 contender (2020) (1)
- Sickle cell disease celebration (2019) (1)
- What is the link between autism and testosterone (2009) (1)
- Merck & Co. pays US$1.35 billion for LSD1 inhibitors (2022) (1)
- The KRAS crowd targets its next cancer mutations (2023) (1)
- Parkinson disease setback (2020) (1)
- EMA provides first glimpse of PRIME candidates (2016) (1)
- The genes that drive speciation (2008) (1)
- CRISPR pioneers win Nobel prize (2020) (1)
- Reverse transcription: Do the flip (2008) (1)
- Consumer gene tests poised for regulatory green light (2012) (1)
- Remyelination researchers regroup after proof-of-concept setback in multiple sclerosis (2016) (1)
- Biotech R&D spending continues to rise (2017) (1)
- FDA approves first new sickle cell drug in 20 years (2017) (1)
- The Nobel Prize-winning path from oxygen sensing research to new drugs (2021) (1)
- Anticoagulant loses its lustre (2012) (1)
- Bob More (2014) (1)
- NIH launches open science Alzheimer initiative (2019) (1)
- Malaria: Picking Plasmodium falciparum apart (2008) (1)
- DPP4 inhibitors dodge cardiovascular bullet (2015) (1)
- Will psychedelics be ‘a revolution in psychiatry’? (2021) (1)
- Chugai reports Actemra deaths (2009) (1)
- RNAi drugs at “a remarkable period of a renaissance” (2021) (1)
- Better screening and disease models needed (2016) (1)
- Symbiosis: Show me the sugar (2008) (1)
- What new GSK patent policy means for the developing world (2016) (1)
- BCMA-targeted bispecific gets first green light, in the EU (2022) (1)
- Tiny springboards detect viruses in fluids (2009) (0)
- What should go into a booster shot for COVID-19? (2022) (0)
- Calculating cancer drug value (2015) (0)
- Novo Nordisk and GlaxoSmithKline buy into RNAi (2021) (0)
- Cytoskeleton: Nibbling away at actin organization (2006) (0)
- Austerity threatens pharma beyond borders of cost cutters (2010) (0)
- Clinical trial transparency, take two (2014) (0)
- Mechanisms of disease: Prions hijack the nanotube (2009) (0)
- What makes a cancer stem cell (2009) (0)
- Industry tightens its purse strings (2009) (0)
- Pfizer buys Trillium and its CD47 candidates for US$2.3 billion (2021) (0)
- Cell migration: The flight of the haemocyte (2006) (0)
- Keith Blundy (2014) (0)
- Next-generation gene-editing platforms drive CRISPR deals (2022) (0)
- GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion (2022) (0)
- Nanog's new trick (2008) (0)
- Kathy High (2021) (0)
- NCATS launches 'periodic table' for medicinal product ingredients (2016) (0)
- FDA approves first anti-IL-36 receptor antibody for rare skin disease (2022) (0)
- AstraZeneca to acquire Alexion (2020) (0)
- Metagenomics: Phages apart (2008) (0)
- In this issue (2007) (0)
- WAH-1 and SCRM-1 make lipids flip (2007) (0)
- Chi-Med scores key approval for 'discovered in China' cancer drug (2018) (0)
- Vertex’s NaV1.8 inhibitor passes phase II pain point (2022) (0)
- PARPs pick-up (2016) (0)
- Immuno-oncology upset in bladder cancer (2017) (0)
- Mike Varney (2015) (0)
- Stanley Crooke (2019) (0)
- Development: Purine to my eyes (2007) (0)
- Cell signalling condensed (2006) (0)
- Eric Karran (2015) (0)
- Dan Tagle (2013) (0)
- Can a platform of platform companies open up more opportunities? (2021) (0)
- Willing subjects live longer but blur clinical trial results (2009) (0)
- In this issue (2007) (0)
- Archaea: Kings of the sea floor? (2008) (0)
- Entasis antibiotic shows phase III promise (2021) (0)
- AstraZeneca to buy rare disease specialist Alexion for $39 billion (2020) (0)
- DNA replication: Follow the path (2008) (0)
- Vertex combo scores a broader cystic fibrosis approval (2015) (0)
- Antibiotics funding splurge gets mixed reception (2016) (0)
- Leena Gandhi (2020) (0)
- Novel excipient review programme aims to bolster formulation innovation (2021) (0)
- Gene therapy pushes the US $1 million price barrier (2014) (0)
- Engineered IL-2 cytokine takes pivotal immuno-oncology blow (2022) (0)
- FDA approves drug from transgenic chicken (2015) (0)
- FDA approves bispecific antibody for two eye diseases (2022) (0)
- Escorting siRNA (2008) (0)
- Jessica Mega (2019) (0)
- Patent income tax slashed (2010) (0)
- Broadly neutralizing antibody misses in HIV prophylaxis trial (2021) (0)
- Roche hits multiple sclerosis landmarks (2015) (0)
- C&EN talks with NCATS’s Christopher Austin (2021) (0)
- Cell/gene potency guides (2008) (0)
- Enbrel patent feud (2008) (0)
- Cell division: Inn a pinch (2008) (0)
- BRAIN gain (2014) (0)
- Development: MicroRNA knocks some sense into senseless (2006) (0)
- Celgene samples from science smorgasbord (2015) (0)
- ADCs inspire large pharma investments (2020) (0)
- Microbial ecology: Baby boom (2007) (0)
- Pierre Meulien (2015) (0)
- Aviv Regev (2021) (0)
- FDA approves first anti-C1s antibody, targeting innate immunity for rare anaemia (2022) (0)
- FDA releases tissue-agnostic cancer drug draft guidance (2022) (0)
- Sandra Horning (2020) (0)
- Of cows and men (2006) (0)
- Emer Cooke (2020) (0)
- Recipes for results (2006) (0)
- R&D budgets boom, but success rates falter (2022) (0)
- From the editors (2007) (0)
- Novartis grows its gene therapy ambitions (2018) (0)
- Chris Austin (2013) (0)
- Human cell assays for new medicines now open access (2015) (0)
- US FDA outlines how to adapt COVID-19 vaccines, drugs and diagnostics to virus variants (2021) (0)
- Phase II antisense sets Crohn disease precedents (2015) (0)
- Melissa Paoloni (2016) (0)
- Systems biology with a view (2006) (0)
- PDUFA V goes back to basics (2012) (0)
- Environmental Microbiology: Arsenic in action (2008) (0)
- Myosin inhibitor flexes, myosin activator flops (2020) (0)
- From the editors (2007) (0)
- Peanut allergy potential (2018) (0)
- From the editors (2007) (0)
- Alzheimer antibody rush begins, as efficacy concerns remain (2021) (0)
- New funding needed for late-stage vaccine work? (2019) (0)
- Large drug firms narrow their therapeutic interests (2014) (0)
- BMS sells diabetes business (2014) (0)
- Reshma Kewalramani (2019) (0)
- AbbVie pays $21 billion for Pharmacyclics' BTK inhibitor (2015) (0)
- Fat busting: the search for a safe and effective diet drug (2012) (0)
- David Urdal (2011) (0)
- From the editors (2007) (0)
- From the editors (2007) (0)
- Open-access fermenter (2010) (0)
- Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors? (2022) (0)
- A new path to targeted protein degradation? (2022) (0)
- Electroceuticals jolt into the clinic, sparking autoimmune opportunities (2022) (0)
- Zafgen charts unique path to obesity approval (2015) (0)
- From the editors (2007) (0)
- Inadvertent parthenogenesis (2007) (0)
- TransCelerate makes progress (2017) (0)
- Protein degradation: Examining E1 (2008) (0)
- Vas Narasimhan (2015) (0)
- Ipsen buys Epizyme for US$247 million (2022) (0)
- Stéphane Bancel (2015) (0)
- Roche buys $1 billion majority stake in Foundation (2015) (0)
- HIV: Do the flip (2008) (0)
- Cellular microbiology: Examining the Fic domain (2009) (0)
- Merck & Co. to buy Acceleron and its TGF-β ligand traps (2021) (0)
- A map of mRNA localization (2007) (0)
- FDA releases proposed terms of PDUFA VII agreement (2021) (0)
- Sage gets an antidepressant lift (2017) (0)
- RSV antibody showcases passive immunotherapy progress (2020) (0)
- In this issue (2007) (0)
- John Jenkins (2017) (0)
- First clinical test of an in vivo CRISPR candidate shows deep protein knockout potential (2021) (0)
- Longer-lasting HIV drugs (2019) (0)
- In this issue (2011) (0)
- What’s next for an immuno-oncology powerhouse? (2021) (0)
- Cell cycle: Achieving entry (2008) (0)
- John Tsai (2019) (0)
- GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline (2022) (0)
- Cancer drug developers counteract kinase gatekeeper mutations (2015) (0)
- Plant stem cells, not so different (2009) (0)
- Cell division: Sensor of tension gets honourable mention (2007) (0)
- Industry gets mixed transparency grades (2015) (0)
- GPRC5D-targeted bispecific bolsters T-cell-engager pipeline (2023) (0)
- In This Issue (2013) (0)
- Francis Cuss (2015) (0)
- Prions: Prions hijack the nanotube (2009) (0)
- RAC to finally relax gene therapy oversight (2014) (0)
- Parsing exceptional responders (2020) (0)
- Mechanisms of disease: A spate of RAB8 (2007) (0)
- FDA tackles gene–drug interactions (2020) (0)
- FDA approves first drug for common form of dwarfism (2021) (0)
- Amgen cues up pivotal KRAS data (2020) (0)
- FDA's rejection of alemtuzumab divides neurologists (2014) (0)
- 15 states sue Amgen (2010) (0)
- Industry gains on moneyback schemes (2010) (0)
- Viral evolution: As the crow dies (2007) (0)
- Ted W. Love (2020) (0)
- PARP inhibitors' revival (2014) (0)
- Where did the membrane go? (2007) (0)
- BMS buys Turning Point Therapeutics and its kinase inhibitors for $4.1 billion (2022) (0)
- From the editors (2007) (0)
- Disease interception at scale: how a five-million-person study plans to transform healthcare (2022) (0)
- Mechanisms of disease: Getting back to β-cell basics (2008) (0)
- Pharma fesses up to freebies (2010) (0)
- Randomness versus order: Whole genome shotgun (2007) (0)
- Web watch (2008) (0)
- Gregory Lip (2012) (0)
- Malaria vaccine shows phase II promise, advances into phase III (2021) (0)
- Neurons on border patrol (2008) (0)
- Bacterial genetics: Resistance in 18 steps (2007) (0)
- 'Mini-hibernation' essential for winter survival (2009) (0)
- Neurodegenerative diseases: Perils of ageing (2006) (0)
- Humans and sponges may share a slimy ancestor (2009) (0)
- Wayne Koff (2014) (0)
- David Liu (2019) (0)
- Pfizer’s small-molecule antiviral misses on COVID prevention (2022) (0)
- Immuno-oncology drugs jostle for first-line setting (2016) (0)
- Henry Chesbrough (2013) (0)
- Development: Sharing the signalling components (2007) (0)
- Protein evolution: Tracing the evolution of structure and function (2007) (0)
- From the editors (2007) (0)
- GSK scores first Phase III shingles trial success (2015) (0)
- Development: A force to be reckoned with (2008) (0)
- In this issue (2010) (0)
- Cloned monkeys yield stem cells (2008) (0)
- The UK Biobank at 20 (2022) (0)
- Antibody clamps pry open small-molecule drug discovery opportunities (2022) (0)
- Tillman Gerngross (2020) (0)
- Meiosis: The telomere bouquet takes control (2007) (0)
- In this issue (2010) (0)
- RNAi deal flow heats up (2018) (0)
- John Reed (2014) (0)
- Sponsors rarely disclose Refuse-to-File letters, finds study of regulatory transparency gap (2021) (0)
- Post-translational modification: Examining the Fic domain (2009) (0)
- Busy panels recommend Pfizer's tofacitinib, Arena's lorcaserin and more (2012) (0)
- Mechanisms of disease: Perils of ageing (2006) (0)
- HIV helpers can be hijacked (2008) (0)
- PCSK9 pipeline (2016) (0)
- Audio long-read: The quest to prevent MS - and understand other post-viral diseases. (2022) (0)
- Reprogrammed skin cells provide testing ground for new drugs (2008) (0)
- Antibiotics take a radical approach (2007) (0)
- FDA approves second anti-amyloid antibody for Alzheimer disease (2023) (0)
- From the editors (2007) (0)
- Should everyone have an HIV test (2008) (0)
- Proof-of-principle Intellia trial shows in vivo CRISPR activity (2022) (0)
- Roche, Biogen and AbbVie stake new gene therapy claims (2019) (0)
- Randy Mills (2015) (0)
- On the hunt for monomeric degraders (2021) (0)
- Circadian rhythms: Setting the clock (2006) (0)
- Andy Plump (2019) (0)
- DNA replication: Follow the path (2008) (0)
- Doug Williams (2014) (0)
- Stem cells: Stemming the tide (2016) (0)
- From pandemic preparedness to public–private partnerships (2022) (0)
- Straight talk with ... Peter Piot (2010) (0)
- Provinces lead the way towards pharmacare in Canada (2017) (0)
- A new pluripotency factor can stand in for two others (2009) (0)
- 'Skin deep' goes to a new depth (2008) (0)
- Drug pricing under the spotlight (2019) (0)
- Cashing in with off-the-shelf CAR Ts (2018) (0)
- Genetics of cancer relapse revealed (2008) (0)
- FDA relaxes cardiovascular trial requirements for diabetes drugs (2020) (0)
This paper list is powered by the following services: